Zobrazeno 1 - 3
of 3
pro vyhledávání: '"R. M. Minnigulov"'
Autor:
K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 16, Iss 5, Pp 670-677 (2020)
Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29
Externí odkaz:
https://doaj.org/article/060e30356f7741b38e1ef181c3cd5e48
Autor:
Dmitry Napalkov, Denis Andreev, R. M. Minnigulov, O. A. Baturina, K. A. Akmalova, I. N. Sychev, A. A. Sokolova, P. O. Bochkov, T. V. Shelekhova, A. I. Kalinkin, A. N. Levanov, D. V. Ivashchenko, A. A. Kachanova, A. I. Skripka, K. B. Mirzaev, D. A. Sychev, T. E. Morozova, I. V. Volodin, Elena A. Grishina
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 5, Pp 670-677 (2020)
Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29
Autor:
T E Morozova, K. A. Ryzhikova, R. M. Minnigulov, A.V. Lychagin, IYu Yudina, Dmitriy A. Sychev
Publikováno v:
Bulletin of Russian State Medical University. :105-109
Rivaroxaban is a safer and more effective alternative to warfarin. However, there are reports of some cases of major hemorrhagic complications associated with rivaroxaban that significantly impair the patients' quality of life and can lead to a fatal